LBA47_PR Phase 3 (P04832) Trial Results for Rolapitant, a Novel Nk-1 Receptor Antagonist, in the Prevention of Chemotherapy-Induced Nausea and Vomiting (Cinv) in Patients Receiving Cisplatin-Based Chemotherapy

Aim: Rolapitant is a highly selective competitive long acting NK-1 receptor antagonist that demonstrated safety and prevention of CINV in both phase 2 and 3 trials. Methods: A multi-center, randomized double-blind phase 3 trial was conducted in patients (pts) receiving cisplatin-based chemotherapy. 532 pts were randomized 1:1 to receive oral rolapitant + granisetron/dexamethasone (G/D) or placebo + G/D prior to chemotherapy. The primary …